LAG-3 is expressed primarily on NK cells, B cells, CD4+, and CD8+ T cells, where it blocks T cell receptor signaling by binding with high affinity to MHC class II molecules, thereby decreasing anti-tumor T cell activity. This evidence concerns the gene CD8A and neoplasm.